Navigation Links
Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe
Date:11/4/2010

BURLINGTON, Mass., Nov. 4, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biosimilar erosion of branded erythropoietin stimulating agent (ESA) market share is likely to be more rapid and more complete in the United States compared to biosimilar erosion seen in Europe since biosimilar ESAs entered the European market in 2007. According to Biosimilars Advisory Service: Physician Perspectives on Erythropoietin Stimulating Agents, Insulin, and Human Growth Hormone, Decision Resources expects the timeline for the uptake of biosimilars among U.S. nephrologists will be fairly aggressive.

More than half of surveyed U.S. physicians anticipate they will begin prescribing a biosimilar ESA within six months of its launch and 88 percent expect to be using biosimilar ESAs within a year. In contrast, the majority of surveyed German nephrologists did not begin using biosimilar ESAs until the drugs had been on the market for 13-24 months. Uptake of biosimilars among surveyed French nephrologists has been even more conservative—60 percent of surveyed physicians report they still do not prescribe biosimilars ESAs.

Decision Resources forecasts that branded ESAs across the seven major pharmaceutical markets (U.S., France, Germany, Italy, Spain, United Kingdom and Japan) will lose $3 billion in combined sales to biosimilar erosion in 2019 alone, and $17.3 billion in combined sales to biosimilar erosion over Decision Resources' 2009-2019 forecast period.

"The global ESA market will be characterized by pricing pressures from a declining market and multiple biosimilar competitors," said Decision Resources Analyst MaryEllen Klusacek, Ph.D. "Biosimilars' lower costs compared with branded biologics will likely be the primary driver of both U.S. and European nephrologists' prescribing of biosimilar ESAs."

The Physician Perspectives on Erythropoietin Stimulating Agents, Insulin, and Human Growth Hormone module of the Biosimilars Advisory Service offers extensive primary research with U.S., French and German nephrologists and endocrinologists to highlight the key expectations that will drive or constrain biosimilar adoption.

Analyst CallMembers of the media are welcome to attend our upcoming analyst call entitled A Forecast of Biosimilars in Nephrology and Endocrinology: How Will Physicians' Perceptions of "Similarity" Affect Prescribing Behavior? This analyst call will be held on Friday, November 12 at 10 a.m. U.S. Eastern Time. For more information, contact Lisa Osgood at losgood@dresources.com.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.Decision ResourcesLisa Osgood781-993-2606losgood@dresources.comDecision Resources, Inc.Christopher Comfort781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncologists Will Be More Aggressive In Adopting Biosimilars Compared With Other Specialties
2. Hospira Receives TGA Approval for Nivestim™, Australias First Biosimilar Filgrastim
3. PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers
4. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
5. Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
6. ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report
7. Biosimilar Insulins and Insulin Analogues Stand to Erode $6.1 Billion in Brand Sales in the U.S. and Europe by 2018
8. Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
9. The Epilepsy Drug Market Will Remain Relatively Flat Through 2019 as Generic Erosion, Especially Within the Second-Generation Antiepileptic Drug Class, is Offset by the Launch of New Therapies
10. Owing to Generic Erosion of Key Agents, the Colorectal Cancer Drug Market Will Remain Relatively Flat Through 2019
11. Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... SAN FRANCISCO , Dec. 2, 2016  PipelineRx, ... clinical telepharmacy, will be offering demonstrations of its ... American Society of Health-System Pharmacists 2016 Midyear Clinical ... Las Vegas . With nearly 300 hospital ... telepharmacy services and technology designed to dramatically improve ...
(Date:12/2/2016)... On Thursday, December 1st 2016, the Prix ... and innovation in the biopharmaceutical industry at its third ... presence of Sergey Tsyb, Vice Minister of Industry and ... Natalia Sanina, First Vice Chairman of the State Duma ... National Service of Control in Healthcare, Sergey Muravev, Director ...
(Date:12/2/2016)...  Eli Lilly and Company (NYSE: LLY ... provide updated financial guidance for 2016 on Thursday, December ... on that day with the investment community and media ... The conference call will begin at 10 a.m. ET. ... live webcast of the conference call through a link ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... Halfway through its partnership with First 5 LA, Western University of Health Sciences’ ... 5 years old and younger and treatment services to more than 9,100 of these ... to Western University of Health Sciences, UCLA and USC, beginning March 1, 2013, to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Two years ago, Arizona State ... watched live by 1 million viewers and won numerous honors, including the region’s ... at the Walter Cronkite School of Journalism and Mass Communication are following up ...
(Date:12/2/2016)... ... ... twenty-four years, Doctors on Liens has published a directory of the top doctors ... When the company started in 1997, the directory was a single page focusing on ... ten-page directory features a vast array of medical specialists stretching from Sacramento to ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Advanced Inc., a ... has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, ... Inc. , Jason brings extensive financial and operational leadership experience to Advanced Inc. ...
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
Breaking Medicine News(10 mins):